Immatics N.V.

NASDAQ:IMTX

Biotechnology

Healthcare
$6.10 +1.58%

+$0.15 today

Market cap
$912.78M
Beta
1.30
P/E (TTM)
-5.3
EPS (TTM)
-$1.59
52W Low $5.05High $12.41

Volume 1.57M

Average 0.46M

IMTX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Immatics N.V.NASDAQ: IMTX

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit declines year over year

Q1 FY2026 gross profit of €7.61M fell 59.0% year over year, ahead of the -74.1% change in trailing-twelve-month gross profit. Sequentially, it fell 61.5% from the prior quarter. Over 3 fiscal years it compounded at -9.9% a year.

Context

  • Gross profit amounted to 100.0% of revenue in FY2025, unchanged from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -59.0% holds above the trailing-twelve-month pace of -74.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€7.61M-61.5% QoQ
Last fiscal yearDec 2025
€48.27M-69.0% YoY
LTMMar 2026
€37.3M-74.1% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-59.0%——
1 year-69.0%——
3-year CAGR-9.9%——
5-year CAGR——
10-year CAGR——

Gross Profit history

EUR · from the income statement

Latest · FY2025
48.27M EUR
Year-over-year change
-69.0%

Gross Profit vs competitors

How IMTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -74.1% is the 9th highest of 11, against a peer median of +19.6%.
  • Gross profit amounts to 100.0% of revenue for IMTX, versus a peer median of 92.4%.
IMTX Competitors
Gross Profit for IMTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€1.87B EUR-18.5%-46.9%70.8%
LEGNLegend Biotech CorporationLTM Sep 2026$774.12M USD+40.6%+129.1%57.0%
IMCRImmunocore Holdings plcLTM Mar 2026$381.15M USD+15.4%+28.0%98.8%
CLLSCellectis S.A.LTM Mar 2026$55.76M USD+43.8%+80.8%81.9%
DTILPrecision BioSciences, Inc.LTM Mar 2026$43.7M USD-14.6%+7.9%97.0%
IMTXImmatics N.V.LTM Mar 2026€37.3M EUR-74.1%-9.9%100.0%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$22.24M USD-86.1%—96.1%
JANXJanux Therapeutics, Inc.LTM Mar 2026$11.7M USD+129.7%+0.9%54.1%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$8.44M USD+91.0%-18.0%92.4%
LYELLyell Immunopharma, Inc.LTM Mar 2026-$2.3M USD-3640.0%—7422.6%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$77.25M USD+23.8%——
Peer median (excluding IMTX) —+19.6%+7.9%92.4%

Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue34.76M172.83M54M155.84M48.27M
Cost of Revenue87.57M106.78M118.66M00
Gross Profit(52.81M)66.05M(64.67M)155.84M48.27M
Gross Margin-151.9%38.2%-119.8%100.0%100.0%
Research & Development87.57M106.78M118.66M148.08M183.83M
Selling, General & Admin33.81M36.12M38.2M46.45M51.18M
Operating Expenses121.05M142.88M155.72M194.45M230.28M
Depreciation & Amortization5.47M6.84M7.23M12.23M12.4M
EBITDA(87.3M)50.04M(88.93M)34.46M(185.09M)
EBITDA Margin-251.1%29.0%-164.7%22.1%-383.5%
Operating Income(86.29M)29.95M(101.73M)(38.62M)(182.02M)
Operating Margin-248.2%17.3%-188.4%-24.8%-377.1%
Interest Income133K2.48M13.85M25M17.18M
Interest Expense566K1.04M831K886K946K
Other Income / Expenses(7.04M)12.08M4.73M59.96M(16.42M)
Income Before Tax(93.34M)42.04M(96.99M)21.35M(198.44M)
Pre-Tax Margin-268.5%24.3%-179.6%13.7%-411.1%
Income Tax Expense04.55M06.13M(1.99M)
Net Income(95.06M)37.51M(96.99M)15.22M(196.45M)
Net Margin-273.5%21.7%-179.6%9.8%-407.0%
EPS (Basic)(1.51)0.55(1.20)0.14(1.54)
EPS (Diluted)(1.51)0.54(1.20)0.14(1.54)
Weighted Avg Shares62.91M67.22M80.55M108.7M122.35M
Weighted Avg Shares (Diluted)62.91M68.82M80.55M106.8M122.35M

Immatics N.V.

NASDAQ:IMTX

Intrinsic Alpha fair value

Locked

Current Price

$6.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.